Market Overview

Why DiaMedica's Stock Is Trading Higher Today

Why DiaMedica's Stock Is Trading Higher Today

DiaMedica Therapeutics (NASDAQ: DMAC) shares are trading higher on Wednesday after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $14 per share.

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company. It is principally engaged in the business activity of developing treatments for unmet clinical need or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

DiaMedica Therapeutics shares traded up 3.19% at $6.96 at time of publication on Wednesday. The stock has a 52-week high of $8.80 and a 52-week low of $1.70.

Latest Ratings for DMAC

Jul 2020Maxim GroupInitiates Coverage OnBuy
May 2020Craig-HallumMaintainsBuy

View More Analyst Ratings for DMAC
View the Latest Analyst Ratings


Related Articles (DMAC)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

CHNGCredit SuisseMaintains19.0
SQCredit SuisseMaintains175.0
DARCredit SuisseInitiates Coverage On50.0
WSFSPiper SandlerMaintains33.0
WNEBPiper SandlerMaintains7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at